ReForm Therapeutics is a globally focused biopharmaceutical company targeting unmet patient needs
Innovation
Through the application of ReForm Therapeutics’ innovative oral mucosal film technology, the company is developing RFX002, a new oro-mucosal formulation of epinephrine, for the emergency treatment of severe allergic reactions (Type I) to insect stings or bites, foods, drugs, and other allergens.
Commercial Focus
The company has a clear focus to rapidly develop RFX002 and drive significant future revenue through commercial partnerships across global markets.
Our strategy is to develop innovative needle-free formulations to a defined value inflection point and then partner with major pharmaceutical and biotechnology companies; under a revenue-generating licence model ReForm will receive royalties and significant milestone payments.
ReForm is applying our drug delivery technologies and development expertise to multiple well-known therapeutics. Currently ReForm is formulating and testing needle-free formulations to treat organophosphate poisoning, diabetes, dental analgesia and severe ulceration of the mouth.